NeuroReset™: A Research-Driven Framework for Neural Recovery
Patent Pending – PATP1280.01 / 1280.04 / App Number 19/381207
© Biotech International Institute — Bill Carrington & Dominic Carrington
Introduction
Neural recovery is one of the most difficult challenges in modern science. A complex web of biological, psychological, and social factors shapes conditions affecting addiction, stress dysregulation, and mood disturbances. At Biotech International Institute, NeuroReset™ is being developed as an investigational platform to better understand how these factors intersect at the level of brain chemistry and neural circuitry. NeuroReset™ is not a therapy, drug, or clinical product. It is an R&D initiative—patent pending and in active development—designed to explore whether a carefully engineered molecular scaffold can help researchers map and eventually test new pathways involved in neural recovery. No claims of safety, efficacy, or clinical utility are being made.
What Is NeuroReset™
NeuroReset™ will be studied as a multi-pathway, neuroactive framework rather than a single-target agent. Instead of focusing exclusively on a single receptor or neurotransmitter, the project examines how a bioengineered scaffold might interface with multiple aspects of brain function.
Current areas of inquiry include:
• Neurotransmitter balance
• Researchers will be studying how targeted chemical designs may influence signaling in brain pathways, including those for dopamine, glutamate, and serotonin. The goal is not to "correct" these systems, but to understand how specific structural motifs may modulate them in controlled experimental settings.
• Neural plasticity
• The program is examining whether specific molecular features correlate with markers of synaptic adaptability in preclinical models, including changes in receptor expression, synaptic connectivity, and activity-dependent signaling cascades.
• Cue and stress reactivity
• Model systems will be used to probe how NeuroReset-inspired scaffolds may influence responsiveness to reward-related cues, stress signals, or affective inputs, with an emphasis on non-clinical, exploratory studies.
It's important to note that all these focus areas will currently be under research. No outcomes have been established, and any effects—whether beneficial or otherwise—will only be demonstrated through rigorous testing in the future.
Architecture & Scientific Rationale
At its core, NeuroReset™ is being designed as a bioengineered, semi-synthetic scaffold. The chemistry strategy draws inspiration from multiple domains:
•Cannabinoid-inspired analogs
• Selected structural elements from cannabinoid research will be used as reference points to tune physicochemical properties and receptor interactions.
Psilocybin-informed cores
• Indole-based architectures and related motifs, studied extensively in psychedelic and neuroplasticity research, provide another conceptual layer for scaffold design. Motifs from neurotrophic mushroom research
• Compounds and structures investigated for their neurotrophic or neuroprotective properties serve as additional sources of design inspiration.
Across these influences, the project aims to evaluate:
• Physicochemical properties relevant to blood–brain barrier transport, such as lipophilicity, molecular weight, and polar surface area.
• Receptor-binding profiles in vitro, with an emphasis on mapping how these scaffolds interact with diverse receptor families and signaling pathways.
• Potential systems-level interactions in non-clinical models, including inflammatory markers, mood-related pathways, and signals associated with neurogenesis or synaptic remodeling.
These design goals are hypothesis-driven and iterative. Additionally, testing and data are collected, the architecture may be refined, re-prioritized, or redirected entirely.
Context and Intended Future Settings
Addiction, stress-related conditions, and mood dysregulation cannot be reduced to a single molecule or pathway. They emerge from a dynamic interplay between biology, lived experience, and environment. NeuroReset™ is being developed against this backdrop, with the long-term question of whether this platform could someday be evaluated in:
• Clinical research environments, such as early-phase and tightly controlled trials
• Integrative care settings, where neurobiological insights may complement psychological and behavioral interventions.
Any such exploration would be contingent on multiple factors:
• Compliance with regulatory requirements in relevant jurisdictions;
• Completion of appropriate safety profiling in preclinical and early-phase studies.
•Accumulation of credible evidence of potential benefit and acceptable risk.
At this time, NeuroReset™ is not cleared or approved for diagnosis, treatment, cure, or prevention of any disease, and is not available for clinical use.
Current Development Status
NeuroReset™ is patent-pending (PATP1280.01 / 1280.04 / App Number 19/381207) and in active research and development at Biotech International Institute. Ongoing activities include:
• Laboratory method development and analytical characterization
• Establishing robust methods for synthesis, purification, quantification, and structural confirmation of candidate molecules.
• Preclinical experimentation
• Conducting in vitro and non-clinical in vivo studies to evaluate receptor interactions, pharmacokinetic properties, and early signals of systems-level effects.
• Collaborative discussions
• Engaging with research institutions, clinical investigators, and other organizations to design potential future studies and non-clinical collaboration frameworks.
All findings from this work will be directed toward one central question: Does the NeuroReset™ approach merit further study in controlled research settings?
Intellectual Property & Collaborative Vision
Biotech International Institute has filed patent applications related to the NeuroReset™ platform and its underlying chemical strategies. All rights are reserved. The Institute's goal is to protect its intellectual property while still enabling rigorous, independent evaluation of the approach.
Partnership discussions are welcomed with:
• Academic and independent research institutions
• Clinical investigators and translational research groups
• Organizations operating at the interface of neurological science and, where relevant, agricultural biotechnology
Potential collaboration topics include study design, materials transfer under appropriate agreements, and non-clinical research programs aimed at clarifying mechanisms, safety profiles, and possible future use cases. We invite interested parties to contact Biotech International Institute to explore structured cooperation possibilities. The expertise and insights of those in our field could be invaluable in increasing our understanding of neural recovery.
Statement of Intent
The guiding principle behind NeuroReset™ is responsible innovation. The team—led by Bill Carrington and Dominic Carrington—is committed to:
• Advancing scientific understanding within transparent, ethically grounded frameworks • Subjecting all hypotheses to careful, data-driven scrutiny
• Communicating results through appropriate scientific and regulatory channels
The aim is not to promote a product, but to determine whether this bioengineered scaffold and its associated framework warrant continued investigation in the service of a better understanding of neural recovery.
Important Notices & Disclaimers
• No medical claims
• The information presented here describes research goals, design concepts, and development status only. It does not assert safety, efficacy, or clinical benefit for NeuroReset™ or any related construct.
• Not a substitute for care
• Nothing in this article constitutes medical advice, diagnosis, or treatment. Individuals should always consult qualified healthcare professionals regarding any health-related questions or conditions.
• Forward-looking statements
• Plans, expectations, and potential applications described for NeuroReset™ are forward-looking and may change based on ongoing experimental results, safety findings, and regulatory guidance.
• IP status
• "Patent pending" indicates that one or more patent applications have been filed. It does not guarantee that a patent will be granted, nor does it define the eventual scope of protection.